A genetic variant of immunoglobulin [gamma]2 is strongly associated with immunity to mucin 1 in patients with breast cancer
High levels of antibodies to mucin 1 (MUC1), a membrane-bound glycoprotein that is overexpressed in adenocarcinomas, are associated with good prognosis in patients with breast cancer. The aim of the present investigation was to determine whether GM and KM allotypes--genetic markers of IgG heavy chai...
Gespeichert in:
| Veröffentlicht in: | Cancer immunology, immunotherapy immunotherapy, 2009-12, Vol.58 (12), p.2025 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | 2025 |
| container_title | Cancer immunology, immunotherapy |
| container_volume | 58 |
| creator | Pandey, Janardan P Nietert, Paul J Klaamas, Kersti Kurtenkov, Oleg |
| description | High levels of antibodies to mucin 1 (MUC1), a membrane-bound glycoprotein that is overexpressed in adenocarcinomas, are associated with good prognosis in patients with breast cancer. The aim of the present investigation was to determine whether GM and KM allotypes--genetic markers of IgG heavy chains and κ-type light chains, respectively--contribute to the magnitude of natural antibody responsiveness to MUC1 in patients with breast cancer. A total of 153 Caucasian subjects with breast cancer were allotyped for several GM and KM markers. These subjects were also characterized for IgG and IgM antibodies to MUC1. Anti-MUC1 IgG antibody levels in subjects who were carriers of the immunoglobulin γ2 allele GM 23 were significantly higher than in those who were noncarriers (P = 0.003). These results could potentially divide the population into high or low responders to MUC1, which has important implications for MUC1-based immunotherapeutic interventions in breast cancer. |
| doi_str_mv | 10.1007/s00262-009-0709-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_213525566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1866235461</sourcerecordid><originalsourceid>FETCH-proquest_journals_2135255663</originalsourceid><addsrcrecordid>eNqNi81KBDEQhIMoOP48gLfG-2gn8-ccRRQfwJvI0huzY5ZJsqZ7lMWXN7A-gJeqouorpa403mjE4ZYRTW9qxLHGoUh7pCrdNqW56_SxqrBpsR4Q21N1xrwtweA4VurnHiYXnXgLX5Q9RYG0AR_CEtM0p_Uy-wivE4VAbwY8A0tOcZr3QMzJehL3Dt9ePg4fL3uQBGGx5aahyI7Euyh8gNbZEQtYitblC3WyoZnd5Z-fq-unx5eH53qX0-fiWFbbtORYppXRTWe6ru-bf0G_kK9VHA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213525566</pqid></control><display><type>article</type><title>A genetic variant of immunoglobulin [gamma]2 is strongly associated with immunity to mucin 1 in patients with breast cancer</title><source>Springer Nature - Complete Springer Journals</source><source>PubMed Central</source><creator>Pandey, Janardan P ; Nietert, Paul J ; Klaamas, Kersti ; Kurtenkov, Oleg</creator><creatorcontrib>Pandey, Janardan P ; Nietert, Paul J ; Klaamas, Kersti ; Kurtenkov, Oleg</creatorcontrib><description>High levels of antibodies to mucin 1 (MUC1), a membrane-bound glycoprotein that is overexpressed in adenocarcinomas, are associated with good prognosis in patients with breast cancer. The aim of the present investigation was to determine whether GM and KM allotypes--genetic markers of IgG heavy chains and κ-type light chains, respectively--contribute to the magnitude of natural antibody responsiveness to MUC1 in patients with breast cancer. A total of 153 Caucasian subjects with breast cancer were allotyped for several GM and KM markers. These subjects were also characterized for IgG and IgM antibodies to MUC1. Anti-MUC1 IgG antibody levels in subjects who were carriers of the immunoglobulin γ2 allele GM 23 were significantly higher than in those who were noncarriers (P = 0.003). These results could potentially divide the population into high or low responders to MUC1, which has important implications for MUC1-based immunotherapeutic interventions in breast cancer.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-009-0709-4</identifier><language>eng</language><publisher>Heidelberg: Springer Nature B.V</publisher><subject>Antibodies ; Antigens ; Breast cancer ; Glycoproteins ; Haplotypes ; Immunoglobulins ; Immunology ; Peptides ; Vaccines</subject><ispartof>Cancer immunology, immunotherapy, 2009-12, Vol.58 (12), p.2025</ispartof><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Pandey, Janardan P</creatorcontrib><creatorcontrib>Nietert, Paul J</creatorcontrib><creatorcontrib>Klaamas, Kersti</creatorcontrib><creatorcontrib>Kurtenkov, Oleg</creatorcontrib><title>A genetic variant of immunoglobulin [gamma]2 is strongly associated with immunity to mucin 1 in patients with breast cancer</title><title>Cancer immunology, immunotherapy</title><description>High levels of antibodies to mucin 1 (MUC1), a membrane-bound glycoprotein that is overexpressed in adenocarcinomas, are associated with good prognosis in patients with breast cancer. The aim of the present investigation was to determine whether GM and KM allotypes--genetic markers of IgG heavy chains and κ-type light chains, respectively--contribute to the magnitude of natural antibody responsiveness to MUC1 in patients with breast cancer. A total of 153 Caucasian subjects with breast cancer were allotyped for several GM and KM markers. These subjects were also characterized for IgG and IgM antibodies to MUC1. Anti-MUC1 IgG antibody levels in subjects who were carriers of the immunoglobulin γ2 allele GM 23 were significantly higher than in those who were noncarriers (P = 0.003). These results could potentially divide the population into high or low responders to MUC1, which has important implications for MUC1-based immunotherapeutic interventions in breast cancer.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Breast cancer</subject><subject>Glycoproteins</subject><subject>Haplotypes</subject><subject>Immunoglobulins</subject><subject>Immunology</subject><subject>Peptides</subject><subject>Vaccines</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNi81KBDEQhIMoOP48gLfG-2gn8-ccRRQfwJvI0huzY5ZJsqZ7lMWXN7A-gJeqouorpa403mjE4ZYRTW9qxLHGoUh7pCrdNqW56_SxqrBpsR4Q21N1xrwtweA4VurnHiYXnXgLX5Q9RYG0AR_CEtM0p_Uy-wivE4VAbwY8A0tOcZr3QMzJehL3Dt9ePg4fL3uQBGGx5aahyI7Euyh8gNbZEQtYitblC3WyoZnd5Z-fq-unx5eH53qX0-fiWFbbtORYppXRTWe6ru-bf0G_kK9VHA</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Pandey, Janardan P</creator><creator>Nietert, Paul J</creator><creator>Klaamas, Kersti</creator><creator>Kurtenkov, Oleg</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20091201</creationdate><title>A genetic variant of immunoglobulin [gamma]2 is strongly associated with immunity to mucin 1 in patients with breast cancer</title><author>Pandey, Janardan P ; Nietert, Paul J ; Klaamas, Kersti ; Kurtenkov, Oleg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2135255663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Breast cancer</topic><topic>Glycoproteins</topic><topic>Haplotypes</topic><topic>Immunoglobulins</topic><topic>Immunology</topic><topic>Peptides</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pandey, Janardan P</creatorcontrib><creatorcontrib>Nietert, Paul J</creatorcontrib><creatorcontrib>Klaamas, Kersti</creatorcontrib><creatorcontrib>Kurtenkov, Oleg</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer immunology, immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pandey, Janardan P</au><au>Nietert, Paul J</au><au>Klaamas, Kersti</au><au>Kurtenkov, Oleg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A genetic variant of immunoglobulin [gamma]2 is strongly associated with immunity to mucin 1 in patients with breast cancer</atitle><jtitle>Cancer immunology, immunotherapy</jtitle><date>2009-12-01</date><risdate>2009</risdate><volume>58</volume><issue>12</issue><spage>2025</spage><pages>2025-</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>High levels of antibodies to mucin 1 (MUC1), a membrane-bound glycoprotein that is overexpressed in adenocarcinomas, are associated with good prognosis in patients with breast cancer. The aim of the present investigation was to determine whether GM and KM allotypes--genetic markers of IgG heavy chains and κ-type light chains, respectively--contribute to the magnitude of natural antibody responsiveness to MUC1 in patients with breast cancer. A total of 153 Caucasian subjects with breast cancer were allotyped for several GM and KM markers. These subjects were also characterized for IgG and IgM antibodies to MUC1. Anti-MUC1 IgG antibody levels in subjects who were carriers of the immunoglobulin γ2 allele GM 23 were significantly higher than in those who were noncarriers (P = 0.003). These results could potentially divide the population into high or low responders to MUC1, which has important implications for MUC1-based immunotherapeutic interventions in breast cancer.</abstract><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s00262-009-0709-4</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer immunology, immunotherapy, 2009-12, Vol.58 (12), p.2025 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_proquest_journals_213525566 |
| source | Springer Nature - Complete Springer Journals; PubMed Central |
| subjects | Antibodies Antigens Breast cancer Glycoproteins Haplotypes Immunoglobulins Immunology Peptides Vaccines |
| title | A genetic variant of immunoglobulin [gamma]2 is strongly associated with immunity to mucin 1 in patients with breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A21%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20genetic%20variant%20of%20immunoglobulin%20%5Bgamma%5D2%20is%20strongly%20associated%20with%20immunity%20to%20mucin%201%20in%20patients%20with%20breast%20cancer&rft.jtitle=Cancer%20immunology,%20immunotherapy&rft.au=Pandey,%20Janardan%20P&rft.date=2009-12-01&rft.volume=58&rft.issue=12&rft.spage=2025&rft.pages=2025-&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-009-0709-4&rft_dat=%3Cproquest%3E1866235461%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213525566&rft_id=info:pmid/&rfr_iscdi=true |